{"name":"Instituto de Olhos de Goiania","slug":"instituto-de-olhos-de-goiania","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ranibizumab and Aflibercept","genericName":"Ranibizumab and Aflibercept","slug":"ranibizumab-and-aflibercept","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"},{"name":"Aflibercept and ranibizumab","genericName":"Aflibercept and ranibizumab","slug":"aflibercept-and-ranibizumab","indication":"Age-related macular degeneration (wet/neovascular)","status":"marketed"}]}],"pipeline":[{"name":"Ranibizumab and Aflibercept","genericName":"Ranibizumab and Aflibercept","slug":"ranibizumab-and-aflibercept","phase":"marketed","mechanism":"Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.","indications":["Neovascular (wet) age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion","Diabetic retinopathy"],"catalyst":""},{"name":"Aflibercept and ranibizumab","genericName":"Aflibercept and ranibizumab","slug":"aflibercept-and-ranibizumab","phase":"marketed","mechanism":"Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.","indications":["Age-related macular degeneration (wet/neovascular)","Diabetic macular edema","Retinal vein occlusion","Diabetic retinopathy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}